Friedrich Schiller University
Jena, Thuringia, 07743, Germany
NCT Number: NCT04113837
The proposed intervention study is designed to evaluate the physiological impact of the regular consumption of the developed foods with improved nutrient profile (verum) in comparison to commercial available foods (control) by a controlled, randomized, double-blind crossover study with patients with measurable cardiovascular risk factors (LDL cholesterol ≥ 120 mg/dl (≥ 3 mmol/l) / Triacylglycerides ≥ 135 mg/dl (≥ 1,5 mmol/l)).
Looking for future studies?
Notify Me25 year–65 year
All sexes
Interventional
Not applicable
Jena, Thuringia, 07743, Germany
The proposed intervention study is designed to evaluate the physiological impact of regularly consumption of the food range with improved nutrient profile (verum) in comparison to commercially available foods (control/placebo).
The controlled, randomized, double-blind crossover study consists of 4-week investigation periods with a 11-week wash-out period in between. Patients (men, female, n = 54 + 6) with measurable cardiovascular risk (LDL cholesterol ≥ 120 mg/dl (≥ 3 mmol/l) / triacylglycerides ≥ 135 mg/dl (≥ 1,5 mmol/l)), are involved.
The product range includes sausages (raw, boiled and cooked varieties) and pasta fortified with dietary fibers, fish oil and plant protein, resulting in a reduction of fat and energy content. Eggs, bread, bread rolls, and mushrooms with higher vitamin D content complete the innovative product range. Additionally, participants receive ice cream where sugar is replaced by xylite.
In the control period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), pasta, eggs, bread, bread rolls, and mushrooms, ice cream) with traditional nutrient profile.
The products will be offered in neutral packaging and are provided regularly by the study team. All personal (participants, physicians) are blinded.
At the beginning, participants are randomly allocated into the verum or the control/placebo group. After the wash-out phase the interventions will be crossed between the groups and the respective products are consumed also for four weeks. In the run-in phase of the study, all patients are invited to a medical examination to ensure the fulfillment of inclusion criteria.
At the beginning and at the end of each study period baseline parameters (BMI, waist-to-hip ratio, blood pressure, bioelectrical impedance measurement) are assessed, lifestyle questionnaires are filled, and venous blood samples are collected for the determination of cardiovascular risk markers.
Subjects document their normal nutritional habits over seven days in a food frequency protocol (FFP) before start and finish of each period. In addition, patients keep a diary for the documentation of nutrition, medication and adverse effects over both study periods.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The food range is comprised of:
sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week
Time frame: change from baseline after 4 weeks
cardiovascular risk factor
Time frame: change from baseline after 4 weeks
total cholesterol, HDL cholesterol, triglycerides in mmol/l
Time frame: change from baseline after 4 weeks
body mass index (kg/m2)
Time frame: change from baseline after 4 weeks
systolic blood pressure (mm Hg) diastolic blood pressure (mmHg)
Time frame: change from baseline after 4 weeks
lipoprotein a (mg/l)
Time frame: change from baseline after 4 weeks
high-sensitive c-reactive protein (mg/dl)
Time frame: change from baseline after 4 weeks
homocysteine (µmol/l)
Time frame: change from baseline after 4 weeks
apolipoproteins A1, B (g/l)
Time frame: change from baseline after 4 weeks
glucose (fasting) (mmol/l)
Time frame: change from baseline after 4 weeks
insulin (fasting) (mU/l)
Time frame: change from baseline after 4 weeks
hemoglobin A1c (fasting) (%)
Time frame: change from baseline after 4 weeks
malodialdehyde modified LDL cholesterol (U/l)
Time frame: change from baseline after 4 weeks
fatty acid distribution in plasma lipids (%FAME)
Time frame: change from baseline after 4 weeks
aspartate transaminase (AST)
Time frame: change from baseline after 4 weeks
alanine transaminase (ALT)
Time frame: change from baseline after 4 weeks
gamma-glutamyltransferase (gGT)
Time frame: change from baseline after 4 weeks
Lactate dehydrogenase (LDH)
Time frame: change from baseline after 4 weeks
cholinesterase
Time frame: change from baseline after 4 weeks
kalium (mmol/l)
Time frame: change from baseline after 4 weeks
transferrin (g/l)
Time frame: change from baseline after 4 weeks
ferritin (µg/l)
Time frame: change from baseline after 4 weeks
body water, body fat, lean body mass, extracellular mass (ECM), body cell mass (BCM)
Time frame: change from baseline after 4 weeks
vitamin A (mmol/l)
Time frame: change from baseline after 4 weeks
vitamin A (nmol/l)
Time frame: change from baseline after 4 weeks
vitamin E (µmol/l)
Time frame: change from baseline after 4 weeks
vitamin B1 (nmol/l)
Time frame: change from baseline after 4 weeks
vitamin B6 (nmol/l)
Time frame: change from baseline after 4 weeks
vitamin B12 (pmol/l)
Time frame: change from baseline after 4 weeks
holotranscobalamine (pmol/l)
Time frame: change from baseline after 4 weeks
creatinine (mmol/24 h)
Time frame: change from baseline after 4 weeks
natrium (mmol/24 h)
Time frame: change from baseline after 4 weeks
magnesium (mmol/24 h)
Time frame: change from baseline after 4 weeks
zinc (µmol/24 h)
Time frame: change from baseline after 4 weeks
albumine (mg/l) (24 h urine)
Time frame: change from baseline after 4 weeks
uric acid (mg/dl) (24 h urine)
University of Jena
Other
Human Intervention Study for Validating the Influence of Regular Consumption of Foods With Improved Nutrient Profile on Cardiovascular Risk Factors
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03558893
Cardiovascular Diseases, Cardiovascular Risk Factor
Portland, Oregon, United States
View Trial DetailsNCT03039023
Cardiovascular Risk Factor
Cleveland, Ohio, United States
View Trial DetailsNCT04731363
Cardiovascular Risk Factor
Cleveland, Ohio, United States
View Trial DetailsNCT03336255
Cardiovascular Risk Factor
Chicago, Illinois, United States
View Trial Details